CYANOQUINOLINE DERIVATIVES Russian patent published in 2016 - IPC C07D405/12 C07D401/14 C07D401/12 A61K31/4709 A61K31/506 A61K31/497 A61K31/5377 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to novel cyanoquinoline derivatives of general formula I, as well as to stereoisomers, cis-trans-isomers or pharmaceutically acceptable salts thereof, where R¹ is selected from a group consisting of 4-bromobut-2-enamide, 4-(dimethylamino)but-2-enamide, acrylamido, but-2-enamide, 3-methylbut-2-enamide, 2-(1-tert-butoxycarbonylpiperidin-4-ylidene) acetamide, 2-(piperidin-4-ylidene)acetamide, 2-(1-methylpiperidin-4-ylidene) acetamide, 2-(1-ethylpiperidin-4-ylidene) acetamide, 2-(1-benzylpiperidin-4-ylidene) acetamide, 2-(1-(2-methoxyethyl) piperidin-4-ylidene)acetamide, 2-(1-(2-methoxycarbonylmethylene)piperidin-4-ylidene)acetamide, 2-(1-isopropylpiperidin-4-ylidene) acetamide, 2-(1-(2-hydroxyethyl)piperidine-4-ylidene)acetamide, 2-(pyrrolidin-3-ylidene)-acetamide, N-(N-(2-(2-(dimethylamino)ethoxy)ethyl)amino)fumaramide, 2-(1-(2-(2-(2-hydroxyethoxy)ethylamino)acetyl) piperidin-4-ylidene)acetamide, 2-((1-methylsulphonyl)piperidin-4-ylidene) acetamide, 4-(piperidin-1-yl)but-2-enamide, 4-(morpholin-4-yl)but-2-enamide, 4-(tert-butylamino)but-2-enamide, 4-(benzylamino)but-2-enamide, 4-(6-hydroxyhexylamino)but-2-enamide, 4-(N-methylbenzylamino)but-2-enamide, 4-(diethylamino)but-2-enamide, 4-(2-methoxyethylamino)but-2-enamide, 4-(diethanolamino)but-2-enamide, 4-(N-methylmethoxyethylamino) but-2-enamide, 4-(N-methyl-ethanolamino)but-2-enamide, 4-(dimethoxyethylamino)but-2-enamide, 4-(N-methyl-6-amino-1-hexanolyl)but-2-enamide and propylamide; one of R² and R³ is H, while other is selected from unsubstituted C₆-aryl-C_1-2-alkyl, substituted with 1-2 substitutes or unsubstituted C₆-aryl and substituted with 1 substitute or unsubstituted 6-9-member heteroaryl, where, when R² or R³ is selected from a substituted C₆-aryl, substitute is selected from C₂-C₆-alkynyl, halogen, C₆-aryl-C₁-alkyloxy (where said C₆-aryl can be substituted with 1 substitute selected from halogen, cyano, C₁-C₆ alkyl, C₁-C-₆ alkoxy), and 6-member heteroaryl-C-₁-alkyloxy, and when R² or R³ are selected from a substituted heteroaryl, substitute is selected from a group comprising C₆-aryl-C₁-alkyl (where said C₆-aryl is optionally substituted with 1 substitute selected from halogen and cyano, methoxy group), C₆-arylamido (where the said C₆-aryl can be unsubstituted or substituted with 1 dimethylamino group), C₆-arylsulphonylamino, C₅-heteroarylamido, C₆-cycloalkylamido, C₆-arylaminocarbonyl (where said C₆-aryl is substituted with 1 methoxy group), C₆-aryl-C₁-alkyloxy and C₆-aryloxy; or R² and R³, together with a nitrogen atom to which they are bonded, form a substituted or unsubstituted 9-10-member heterocyclyl, where heterocycyl substitutes are selected from halogen, C₁-C-₆ alkyl, CF₃, C₆-aryl-C₁-alkoxy, -COOMe, -CH₂OH and pyrrolyl; and R⁴ is substituted with 1 methyl or unsubstituted 5-6-member heterocyclyl or unsubstituted 6-member heteroaryl. Invention also relates to specific compounds, pharmaceutical composition based on compound of formula I and use of formula I.

EFFECT: technical result is obtaining novel cyanoquinoline derivatives which are useful in treating tumours.

33 cl, 20 tbl, 228 ex